{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:44:55Z","timestamp":1777488295983,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["MD\/PhD Grand 2018"],"award-info":[{"award-number":["MD\/PhD Grand 2018"]}],"id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["MD\/PhD Grand 2018"],"award-info":[{"award-number":["MD\/PhD Grand 2018"]}],"id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03868-2","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T14:16:21Z","timestamp":1734790581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy"],"prefix":"10.1007","volume":"74","author":[{"given":"S. J.","family":"Luk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"IJsselsteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Somarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Acem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Briaire","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Szuhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. V. M. G.","family":"Bovee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. F. C. C.","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H. F.","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. H. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"3868_CR1","unstructured":"WHO classification of tumours editorial board (2020) Soft tissue and bone tumours, WHO classification of tumours, 5th editon, IARC pres 3"},{"issue":"6","key":"3868_CR2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1349-7006.2009.01134.x","volume":"100","author":"Y Sun","year":"2009","unstructured":"Sun Y et al (2009) Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci 100(6):1018\u20131025","journal-title":"Cancer Sci"},{"issue":"12","key":"3868_CR3","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00264-020-04708-5","volume":"44","author":"L Xiong","year":"2020","unstructured":"Xiong L et al (2020) The survival and prognosis analysis of synovial sarcoma subtypes: a surveillance, epidemiology, and end results population-based analysis. Int Orthop 44(12):2779\u20132786","journal-title":"Int Orthop"},{"issue":"10","key":"3868_CR4","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.7150\/jca.17349","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S et al (2017) Survival changes in patients with synovial sarcoma, 1983\u20132012. J Cancer 8(10):1759\u20131768","journal-title":"J Cancer"},{"issue":"20","key":"3868_CR5","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.2004.11.093","volume":"22","author":"L Guillou","year":"2004","unstructured":"Guillou L et al (2004) Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 22(20):4040\u20134050","journal-title":"J Clin Oncol"},{"issue":"1","key":"3868_CR6","first-page":"135","volume":"62","author":"M Ladanyi","year":"2002","unstructured":"Ladanyi M et al (2002) Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62(1):135\u2013140","journal-title":"Cancer Res"},{"issue":"15","key":"3868_CR7","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/cncr.24424","volume":"115","author":"I Sultan","year":"2009","unstructured":"Sultan I et al (2009) Comparing children and adults with synovial sarcoma in the surveillance, epidemiology, and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer 115(15):3537\u20133547","journal-title":"Cancer"},{"issue":"1","key":"3868_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"S Sleijfer","year":"2010","unstructured":"Sleijfer S et al (2010) Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG). Eur J Cancer 46(1):72\u201383","journal-title":"Eur J Cancer"},{"issue":"25","key":"3868_CR9","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 Inhibition. N Engl J Med 377(25):2500\u20132501","journal-title":"N Engl J Med"},{"issue":"10304","key":"3868_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014","journal-title":"Lancet"},{"key":"3868_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/168145","volume":"2013","author":"RG Maki","year":"2013","unstructured":"Maki RG et al (2013) A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013:168145","journal-title":"Sarcoma"},{"issue":"11","key":"3868_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18(11):1493\u20131501","journal-title":"Lancet Oncol"},{"issue":"9","key":"3868_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","volume":"23","author":"N Somaiah","year":"2022","unstructured":"Somaiah N et al (2022) Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol 23(9):1156\u20131166","journal-title":"Lancet Oncol"},{"issue":"12","key":"3868_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.20.03452","volume":"40","author":"SP Chawla","year":"2022","unstructured":"Chawla SP et al (2022) Phase II randomized study of CMB305 and Atezolizumab compared With Atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol 40(12):1291\u20131300","journal-title":"J Clin Oncol"},{"key":"3868_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.humpath.2020.04.007","volume":"100","author":"M He","year":"2020","unstructured":"He M et al (2020) Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. Hum Pathol 100:15\u201323","journal-title":"Hum Pathol"},{"issue":"8","key":"3868_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/biomedicines9081048","volume":"9","author":"S van Oost","year":"2021","unstructured":"van Oost S et al (2021) Linking immunity with genomics in sarcomas: is genomic complexity an immunogenic trigger? Biomedicines 9(8):1048. https:\/\/doi.org\/10.3390\/biomedicines9081048","journal-title":"Biomedicines"},{"issue":"1","key":"3868_CR17","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva A et al (2022) Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun 13(1):5296","journal-title":"Nat Commun"},{"issue":"1","key":"3868_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS et al (2023) Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med 29(1):104\u2013114","journal-title":"Nat Med"},{"issue":"10","key":"3868_CR19","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/cas.13769","volume":"109","author":"N Oike","year":"2018","unstructured":"Oike N et al (2018) Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 109(10):3043\u20133054","journal-title":"Cancer Sci"},{"issue":"2","key":"3868_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2326-6066.CIR-16-0148","volume":"5","author":"TS Nowicki","year":"2017","unstructured":"Nowicki TS et al (2017) Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res 5(2):118\u2013126","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3868_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41598-023-28024-1","volume":"13","author":"M Umakoshi","year":"2023","unstructured":"Umakoshi M et al (2023) Macrophage numbers in the marginal area of sarcomas predict clinical prognosis. Sci Rep 13(1):1290","journal-title":"Sci Rep"},{"issue":"8","key":"3868_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-21-4239","volume":"28","author":"PH Goff","year":"2022","unstructured":"Goff PH et al (2022) Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells. Clin Cancer Res 28(8):1701\u20131711","journal-title":"Clin Cancer Res"},{"key":"3868_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/2326-6066.CIR-22-0759","volume":"11","author":"SJ Luk","year":"2023","unstructured":"Luk SJ et al (2023) VISTA expression on cancer-associated endothelium selectively prevents T-cell extravasation. Cancer Immunol Res 11:1480\u20131892","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3868_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cjp2.113","volume":"5","author":"ME Ijsselsteijn","year":"2019","unstructured":"Ijsselsteijn ME et al (2019) Cancer immunophenotyping by seven-colour multispectral imaging without tyramide signal amplification. J Pathol Clin Res 5(1):3\u201311","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"3868_CR25","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7(1):16878","journal-title":"Sci Rep"},{"issue":"7","key":"3868_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676\u2013682","journal-title":"Nat Methods"},{"issue":"12","key":"3868_CR27","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","volume":"16","author":"S Berg","year":"2019","unstructured":"Berg S et al (2019) ilastik: interactive machine learning for (bio)image analysis. Nat Methods 16(12):1226\u20131232","journal-title":"Nat Methods"},{"issue":"1","key":"3868_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling DR et al (2021) CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 22(1):433","journal-title":"BMC Bioinformatics"},{"key":"3868_CR29","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.3389\/fimmu.2019.02534","volume":"10","author":"ME Ijsselsteijn","year":"2019","unstructured":"Ijsselsteijn ME et al (2019) A 40-marker panel for high dimensional characterization of cancer immune microenvironments by imaging mass cytometry. Front Immunol 10:2534","journal-title":"Front Immunol"},{"key":"3868_CR30","doi-asserted-by":"crossref","unstructured":"Ijsselsteijn ME et al (2021) Semi-automated background removal limits data loss and normalizes imaging mass cytometry data. Cytometry A","DOI":"10.1101\/2020.11.26.399717"},{"issue":"1","key":"3868_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1109\/TVCG.2019.2931299","volume":"27","author":"A Somarakis","year":"2021","unstructured":"Somarakis A et al (2021) ImaCytE: visual exploration of cellular micro-environments for imaging mass cytometry data. IEEE Trans Vis Comput Graph 27(1):98\u2013110","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"3","key":"3868_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477\u2013486","journal-title":"Nat Med"},{"issue":"11","key":"3868_CR33","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M et al (2022) Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol 24(11):1935\u20131949","journal-title":"Neuro Oncol"},{"issue":"5","key":"3868_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3868_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00129039-200609000-00009","volume":"14","author":"Y Ge","year":"2006","unstructured":"Ge Y et al (2006) Reduced CD1d expression in colonic epithelium in microscopic colitis. Appl Immunohistochem Mol Morphol 14(3):309\u2013313","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"3868_CR36","doi-asserted-by":"publisher","first-page":"C1807","DOI":"10.1152\/ajpcell.00069.2022","volume":"323","author":"P Rousselle","year":"2022","unstructured":"Rousselle P, Laigle C, Rousselet G (2022) The basement membrane in epidermal polarity, stemness, and regeneration. Am J Physiol Cell Physiol 323(6):C1807-c1822","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"3868_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/030089169307900612","volume":"79","author":"M Guarino","year":"1993","unstructured":"Guarino M (1993) Immunohistochemical distribution of basement membrane type IV collagen and laminin in synovial sarcoma. Tumori 79(6):427\u2013432","journal-title":"Tumori"},{"issue":"12","key":"3868_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1507600","volume":"7","author":"SJ Luk","year":"2018","unstructured":"Luk SJ et al (2018) PRAME and HLA class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. Oncoimmunology 7(12):e1507600","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03868-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03868-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:50:11Z","timestamp":1738259411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03868-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3868"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03868-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"31"}}